Until 2022, patients in the public health systemwere not allowed to receive cinacalcet unless they had a serum PTH higher than 800pg/mL or persistent hypercalcemia or hyperphosphatemia and a documented failure toachieve adequate PTH levels with VDRAs17. This evidence concerns the gene PTH and hyperphosphatemia.